ADA/APA (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596–601.
Allen, MH, Forster, P, Zealberg, J, Currier, G (2002). Report and Recommendations Regarding Psychiatric Emergency and Crisis Services. A Review and Model Program Descriptions. APA Task Force on Psychiatric Emergency Services. American Psychiatric Association (www.psych.org/edu/otherres/libarchives/archives/tfr/tfr200201.pdf).
Amati, A, Biondi, M, Bogetto, F, Casacchia, M, Castrogiovanni, P, Giorgino, F, Muscettola, G, Placidi, G, Rossi, A, Ravizza, L (2006). Metabolic syndrome and related disorders in schizophrenia. Guidelines for medical monitoring [in Italian]. Giornale Italiano di Psicopatologia 12 (Suppl. 1), 5–14.
Arango, C, Bobes, J, Aranda, P, Carmena, R, Garcia-Garcia, M, Rejas, J; CLAMORS Study Collaborative Group (2008). A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophrenia Research 104, 1–12.
Arce-Cordon, R, Perez-Rodriguez, MM, Baca-Baldomero, E, Oquendo, MA, Baca-Garcia, E (2007). Routine laboratory screening among newly admitted psychiatric patients: is it worthwhile? Psychiatric Services 58, 1602–1605.
Balf, G, Stewart, T, Whitehead, R, Baker, R (2008). Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Primary Care Companion to the Journal of Clinical Psychiatry 10, 15–24.
Banta, J, Morrato, E, Lee, S, Haviland, M (2009). Retrospective analysis of diabetes care in California Medicaid patients with mental illness. Journal of General Internal Medicine 24, 802–808.
Barnes, TRE, Paton, C, Hancock, E, Cavanagh, MR, Taylor, D, Lelliott, P (2008). Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatrica Scandinavica 118, 26–33.
Barnett, A, Mackin, P, Chaudhury, I, Farooqi, A, Gadsby, R, Heald, A, Hill, J, Millar, H, Peveler, R, Rees, A, Singh, V, Taylor, D, Vora, J, Jones, P (2007). Minimising metabolic and cardiovascular risk in schizophrenia, diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology 21, 357–373.
Batscha, C, Schneiderhan, M, Kataria, Y, Rosen, C, Marvin, R (2010). Treatment settings and metabolic monitoring for people experiencing first-episode psychosis. Journal of Psychosocial Nursing and Mental Health Services 48, 44–49.
Bauer, M, Lecrubier, Y, Suppes, T (2008). Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists. European Psychiatry 23, 169–177.
Begg, CB, Mazumdar, M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101.
Bell, R, Farmer, S, Ries, R, Srebnik, D (2009). Metabolic risk factors among Medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatric Services 60, 1686–1689.
Bernardo, M, Cañas, F, Banegas, J, Casademont, J, Riesgo, Y, Varela, C; RICAVA Study Group (2009). Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. European Psychiatry 24, 431–441.
Bobes, J, Alegría, A, Saiz-Gonzalez, M, Barber, I, Pérez, J, Saiz-Ruiz, J (2010). Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. European Psychiatry. Published online: 11 June 2010. doi:10.1016/j.eurpsy.2010.04.004.
Boilson, M, Hamilton, R (2003). A survey of monitoring of weight and blood glucose in inpatients. Psychiatric Bulletin 27, 424–426.
Bresee, L, Majumdar, S, Patten, S, Johnson, J (2010 a). Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophrenia Research 117, 75–82.
Bresee, L, Majumdar, S, Patten, S, Johnson, J (2010 b). Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. European Psychiatry. Published online: 13 July 2010. doi:10.1016/j.eurpsy.2010.05.003.
Buckley, P, Miller, D, Singer, B, Arena, J, Stirewalt, E (2005). Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research 79, 281–288.
Cabana, M, Rand, C, Powe, N, Wu, A, Wilson, M, Abboud, P, Rubin, H (1999). Why don't physicians follow clinical practice guidelines? A framework for improvement. Journal of the American Medical Association 282, 1458–1465.
Cahn, W, Ramlal, D, Bruggeman, R, de Haan, L, Scheepers, F, van Soest, M, Assies, J, Slooff, C (2008). Prevention and treatment of somatic complications arising from the use of antipsychotics [in Dutch]. Tijdschrift voor Psychiatrie 50, 579–591.
Chen, H, Reeves, J, Fincham, J, Kennedy, W, Dorfman, J, Martin, B (2006). Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrolees in 2001. Journal of Clinical Psychiatry 67, 972–982.
Cochrane, L, Olson, C, Murray, S, Dupuis, M, Tooman, T, Hayes, S (2007). Gaps between knowing and doing, understanding and assessing the barriers to optimal health care. Journal of Continuing Education in the Health Professions 27, 94–102.
Colton, C, Manderscheid, R (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3, A42.
Copeland, L, Parchman, M, Zeber, J, Lawrence, V, Downs, J, Miller, A (2010). Prediabetes assessment and follow-up in older veterans with schizophrenia. American Journal of Geriatric Psychiatry 18, 887–896.
Correll, C, Harris, J, Pantaleon Moya, R, Frederickson, A, Kane, J, Manu, P (2007). Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics, missed targets and lost opportunities. Schizophrenia Research 92, 103–107.
Crabb, J, McAllister, M, Blair, A (2009). Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team. Early Intervention in Psychiatry 3, 312–316.
Crossley, NA, Constante, M, McGuire, P, Power, P (2010). Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. British Journal of Psychiatry 196, 434–439.
De Hert, M, Bobes, J, Cetkovich-Bakmas, M, Cohen, D, Leucht, S, Uwakwe, R, Bobes, J, Moller, H, Cetkovich-Bakmas, M, Ndetei, D, Newcomer, J, Asai, I, Gautman, S, Detraux, J (in press a). Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual level. World Psychiatry 10, 138–151.
De Hert, M, Correll, CU, Bobes, J, Cetkovich-Bakmas, M, Cohen, D, Asai, Y, Detraux, J, Gautam, S, Möller, H, Ndetei, D, Newcomer, J, Uwakwe, J, Leucht, S (2011). Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10, 52–77.
De Hert, M, Dekker, J, Wood, D, Kahl, K, Holt, R, Möller, H (2009). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 24, 412–424.
De Hert, M, Falissard, B, Mauri, M, Shaw, K, Wetterling, T (2008). Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: the METEOR study. European Neuropsychopharmacology 18, S444.
De Hert, M, Vancampfort, D, Correll, CU, Mercken, V, Peuskens, J, Sweers, K, van Winkel, R, Mitchell, AJ (in press b). A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia. British Journal of Psychiatry.
De Nayer, A, De Hert, M, Scheen, A, Van Gaal, L, Peuskens, J (2005). Belgian consensus on metabolic problems associated with atypical antipsychotics. International Journal of Psychiatry in Clinical Practice 9, 130–137.
Desai, M, Rosenheck, RA, Druss, BG, Perlin, JB (2002). Mental disorders and quality of diabetes care in the Veterans Health Administration. American Journal of Psychiatry 159, 1584–1590.
Dinan, T, Holt, R, Kohen, D, Thakore, J, Haddad, P, Baker, R, Peet, M, Gough, S (2004). ‘Schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3–4 October 2003: consensus summary. British Journal of Psychiatry. Supplement 47, S112–S114.
Dixon, LB, Kreyenbuhl, JA, Dickerson, FB, Donner, TW, Brown, CH, Wohlheiter, K, Postrado, L, Goldberg, RW, Fang, L, Marano, C, Messias, E (2004). A comparison of type II diabetes outcomes among persons with and without severe mental illness. Psychiatric Services 55, 892–900.
Elkis, H, Gama, C, Suplicy, H, Tambascia, M, Bressan, R, Lyra, R, Cavalcante, S, Minicucci, L (2008). Brazilian consensus on second-generation antipsychotics and metabolic disorders [in Portuguese]. Revista Brasileira de Psiquiatria 30, 77–85.
Fleischhacker, W, Cetkovich-Bakmas, M, De Hert, M, Hennekens, C, Lambert, M, Leucht, S, Maj, M, McIntyre, R, Naber, D, Newcomer, J, Olfson, M, Osby, U, Sartorius, N, Lieberman, J (2008). Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of Clinical Psychiatry 69, 514–519.
Forsner, T, Hansson, J, Brommels, M, Wistedt, AA, Forsell, Y (2010). Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers. BMC Psychiatry 10, 8.
Francke, A, Smit, M, de Veer, A, Mistiaen, P (2008). Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Medical Informatics and Decision Making 8, 38.
Frayne, S, Halanych, J, Miller, D, Wang, F, Lin, H, Pogach, L, Sharkansky, E, Keane, T, Skinner, K, Rosen, C, Berlowitz, D (2005). Disparities in diabetes care, impact of mental illness. Archives of Internal Medicine 165, 2631–2638.
Goldberg, R, Kreyenbuhl, J, Medoff, D, Dickerson, F, Wohlheiter, K, Fang, L, Brown, C, Dixon, L (2007). Quality of diabetes care among adults with serious mental illness. Psychiatric Services 58, 536–543.
Gonzalez, C, Ahammed, N, Fisher, R (2010). Improving physical health monitoring for out-patients on antipsychotic medication. Psychiatric Bulletin 34, 91–94.
Gothefors, D, Adolfsson, R, Attvall, S, Erlinge, D, Jarbin, H, Lindström, K, von Hausswolff-Juhlin, YL, Morgell, R, Toft, E, Osby, U (2011). Swedish clinical guidelines: prevention and management of metabolic risk in patients with severe psychiatric disorders. Nordic Journal of Psychiatry 64, 294–302.
Grol, R (2001). Success and failures in the implementation of evidence-based guidelines for clinical practice. Medical Care 39, 1146–1154.
Gul, M, Nihgam, A, Broughton, N (2006). Clinical monitoring of patients on clozapine. Journal of Pakistan Psychiatric Society 3, 90.
Gumber, R, Mizrab, A, Minajagiet, M (2010). Monitoring the metabolic side-effects of atypical antipsychotics. The Psychiatrist 34, 390–395.
Haupt, D, Rosenblatt, L, Kim, E, Baker, R, Whitehead, R, Newcomer, J (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry 166, 345–353.
Hetrick, S, Alvarez-Jiménez, M, Parker, A, Hughes, F, Willet, M, Morley, K, Fraser, R, McGorry, PD, Thompson, A (2010). Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic. Australasian Psychiatry 18, 451–455.
Holt, R, Abdelrahman, T, Hirsch, M, Dhesi, Z, George, T, Blincoe, T, Peveler, R (2009). The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of Psychopharmacology 24, 867–873.
Horvitz-Lennon, M, Kilbourne, AM, Pincus, HA (2006). From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Affairs 25, 659–669.
Hsu, C, Ried, L, Bengtson, M, Garman, P, McConkey, J, Rahnavard, F (2008). Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association 48, 393–400.
Jennex, A, Gardner, D (2008). Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Canadian Journal of Psychiatry 53, 34–42.
Jin, H, Meyer, J, Jeste, D (2004). Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 71, 195–212.
Jones, L, Clarke, W, Carney, CP (2004). Receipt of diabetic services by insured adults with and without claims for mental disorders. Medical Care 42, 1167–1175.
Khatana, S, Kane, J, Taveira, T, Bauer, M, Wu, W (2011). Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One 6, e19298.
Kilbourne, A, Post, E, Bauer, M, Zeber, J, Copeland, L, Good, C, Pincus, H (2007). Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. Journal of Affective Disorders 102, 145–151.
Krein, S, Bingham, R, McCarthy, J, Mitchinson, A, Payes, J, Valenstein, M (2006). Diabetes treatment among VA patients with comorbid serious mental illness. Psychiatric Services 57, 1016–1021.
Kreyenbuhl, J, Dickerson, F, Medoff, D, Brown, CH, Goldberg, RW, Fang, L, Wohlheiter, K, Mittal, LP, Dixon, L (2006). Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. Journal of Nervous and Mental Disease 194, 404–410.
Lambert, T, Chapman, L (2004). Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Medical Journal of Australia 181, 544–548.
Lambert, T, Newcomer, J (2009). Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Medical Journal of Australia 190, S39–S41.
Lefebvre, N, Chereau, I, Schmitt, A, Llorca, P-M (2006). Comorbidités somatiques chez les patients souffrant de schizophrénie traitée. Recommandations actuelles. Annales Medico Psychologiques 164, 159–164.
Leucht, S, Burkard, T, Henderson, J, Maj, M, Sartorius, N (2007). Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 116, 317–333.
Lord, O, Malone, D, Mitchell, AJ (2010). Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. General Hospital Psychiatry 32, 519–543.
Mackin, P, Bishop, D, Watkinson, H (2007). A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 25, 7–28.
Mangurian, C, Goss, E, Newcomer, J (2010). Metabolic screening and treatment references of Hispanic inpatients. Psychiatric Services 61, 1161–1162.
Marder, S, Essock, S, Miller, A, Buchanan, R, Casey, D, Davis, J, Kane, J, Lieberman, J, Schooler, N, Covell, N, Stroup, S, Weissman, E, Wirshing, D, Hall, C, Pogach, L, Pi-Sunyer, X, Bigger, J, Friedman, A, Kleinberg, D, Yevich, S, Davis, B, Shon, S (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161, 1334–1349.
McEvoy, J, Meyer, J, Goff, D, Nasrallah, H, Davis, S, Sullivan, L, Meltzer, H, Hsiao, J, Scott Stroup, T, Lieberman, J (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80, 19–32.
McIntyre, R, Leiter, L, Yale, J, Lau, D, Ur, E, Poulin, M, Cook, P, Konarski, J, McFarlane, J, Seguin, F (2005). Schizophrenia, glycemia and antipsychotic medications: an expert consensus review. Canadian Journal of Diabetes 29, 113–121.
Melkersson, K, Dahl, M, Hulting, A (2004). Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism. Psychopharmacology 175, 1–6.
Meyer, J, Koro, C (2004). The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 70, 1–17.
Meyer, J, Nasrallah, H, McEvoy, J, Goff, D, Davis, S, Chakos, M, Patel, J, Keefe, R, Stroup, T, Lieberman, J (2005). The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 80, 9–18.
Millar, H (2010). Development of a health screening clinic. European Psychiatry 25 (Suppl. 2), 29–33.
Mitchell, AJ (2009). Do antipsychotics cost lives or save lives? Risks versus benefits from large epidemiological studies. Journal of Clinical Psychopharmacology 29, 517–519.
Mitchell, AJ, Lord, O (2010). Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. Journal of Psychopharmacology 24, 69–80.
Mitchell, AJ, Malone, D (2006). Physical health and schizophrenia. Current Opinion in Psychiatry 19, 432–437.
Mitchell, AJ, Malone, D, Doebbeling, CC (2009). Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. British Journal of Psychiatry 194, 491–499.
Moeller, KE, Rigler, SK, Mayorga, A, Nazir, N, Shireman, TI (2011). Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research 126, 117–123.
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG; PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. British Medical Journal 339, b2535.
Morrato, EH, Cuffel, B, Newcomer, JW, Lombardo, I, Kamat, S, Barron, J (2009 a). Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. Journal of Clinical Psychopharmacology 29, 26–32.
Morrato, EH, Druss, B, Hartung, D, Valuck, RJ, Allen, R, Campagna, E, Newcomer, J (2010). Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry 67, 17–24.
Morrato, EH, Newcomer, JW, Allen, RR, Valuck, RJ (2008). Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. Journal of Clinical Psychiatry 69, 316–322.
Morrato, EH, Newcomer, JW, Kamat, S, Baser, O, Harnett, J, Cuffel, B (2009 b). Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32, 1037–1042.
Motsinger, C, Slack, M, Weaver, M, Reed, M (2006). Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study. Primary Care Companion to the Journal of Clinical Psychiatry 8, 220–223.
Murasaki, M, Koyama, T, Atsumi, Y, Kadowaki, T (2008). Proposal of monitoring guidance for blood glucose in patients treated with second generation (atypical) antipsychotics. Japanese Journal of Clinical Psychopharmacology 11, 1139–1148.
Nasrallah, H, Meyer, J, Goff, D, McEvoy, J, Davis, S, Stroup, T, Lieberman, J (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86, 15–22.
Natarajan, M, D'Silva, K (2007). Blood glucose monitoring in a regional secure unit. The Psychiatrist 31, 234. doi:10.1192/pb.31.5.234b.
Newcomer, J (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19, 1–93.
Nguyen, D, Brakoulias, V, Boyce, P (2009). An evaluation of monitoring practices in patients on second generation antipsychotics. Australasian Psychiatry 17, 295–299.
Organ, B, Nicholson, E, Castle, D (2010). Implementing a physical health strategy in a mental health service. Australasian Psychiatry 18, 456–459.
Oriot, P, Feys, J, de Wilmars, S, Misson, A, Ayache, L, Fagnart, O, Gruson, D, Luts, A, Jamart, J, Hermans, M, Buysschaert, M (2008). Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes and Metabolism 34, 490–496.
Paton, C, Esop, R, Young, C, Taylor, D (2004). Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica 110, 299–305.
Pincus, H (2010). From PORT to policy to patient outcomes: crossing the quality chasm. Schizophrenia Bulletin 36, 109–111.
Poulin, M, Cortese, L, Williams, R, Wine, N, McIntyre, RS (2005). Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Canadian Journal of Psychiatry 50, 555–562.
Rosack, J (2003). FDA to require diabetes warning on antipsychotics. Psychiatric News 38, 1.
Rummel-Kluge, C, Komossa, K, Schwarz, S, Hunger, H, Schmid, F, Lobos, CA, Kissling, W, Davis, JM, Leucht, S (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123, 225–233.
Saha, S, Chant, D, McGrath, J (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64, 1123–1131.
Saiz, J, Bobes, G, Vallejo, J, Giner, J, Garcia-Portilla, M (2008). Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry [in Spanish]. Actas Espanolas de Psiquiatria 36, 251–264.
Salokangas, RKR, Hirvonen, J, Honkonen, T, Jyväsjärvi, S, Koponen, H, Laukkale, T, Wahlbeck, K (2001). Schizophrenia treatment guideline update. Duodecim 117, 2640–2657.
Saravane, D, Feve, B, Frances, Y, Corruble, E, Lancon, C, Chanson, P, Maison, P, Terra, J, Azorin, J (2009). Drawing up guidelines for the attendance of physical health of patients with severe mental illness [in French]. L'Encéphale 35, 330–339.
Sheldon, TA, Cullum, N, Dawson, D, Lankshear, A, Lowson, K, Watt, I, West, P, Wright, D, Wright, J (2004). What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes and interviews. British Medical Journal 329, 999–1004.
Shi, L, Ascher-Svanum, H, Chiang, Y, Zhao, Y, Fonseca, V, Winstead, D (2009). Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry 9, 80.
Smith, M, Hopkins, D, Peveler, R, Holt, R, Woodward, M, Ismail, K (2008). First- versus second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 192, 406–411.
Staller, J, Wade, M, Baker, M (2005). Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. Journal of Child and Adolescent Psychopharmacology 15, 57–61.
Suppes, T, McElroy, S, Hirschfeld, R (2007). Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder, a survey of 500 US psychiatrists. Psychopharmacology Bulletin 40, 22–37.
Szpakowicz, M, Herd, A (2008). ‘Medically cleared’: how well are patients with psychiatric presentations examined by emergency physicians? Journal of Emergency Medicine 35, 369–372.
Tarrant, C (2006). Blood glucose testing for adults prescribed atypical antipsychotics in primary and secondary care. Psychiatric Bulletin 30, 286–288.
Taylor, D, Young, C, Esop, R, Paton, C, Walwynt, R (2004). Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. British Journal of Psychiatry 185, 152–156.
Taylor, D, Young, C, Mohamed, R, Paton, C, Walwyn, R (2005). Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. Journal of Psychopharmacology 19, 182–186.
Usher, K, Foster, K, Park, T (2006). The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management. Journal of Psychiatric and Mental Health Nursing 13, 730–734.
Verdoux, H, Boulon, S, Cougnard, A (2008). Gender differences in metabolic monitoring of second-generation antipsychotic prescriptions. Human Psychopharmacology 23, 471–474.
Voruganti, LP, Punthakee, Z, Van Lieshout, RJ, MacCrimmon, D, Parker, G, Awad, AG, Gerstein, HC (2007). Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. Schizophrenia Research 96, 215–222.
Weinmann, S, Read, J, Aderhold, V (2009). Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 113, 1–11.
Weiss, A, Henderson, D, Weilburg, J, Goff, D, Meigs, J, Cagliero, E, Grant, R (2006). Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatric Services 57, 1145–1152.
Weissman, E, Zhu, C, Schooler, N, Goetz, R, Essock, SM (2006). Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. Clinical Psychiatry 67, 1323–1326.
Yood, M, Delorenze, G, Quesenberry, CP, Oliveria, S, Tsai, A, Willey, V, McQuade, R, Newcomer, J, L'Italien, G (2009). The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiology and Drug Safety 18, 791–799.